Treatment Resistant Depression - Pipeline Review, H1 2016

  • ID: 3734746
  • Report
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics, Inc.
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • MORE
Treatment Resistant Depression - Pipeline Review, H1 2016

Summary

‘Treatment Resistant Depression - Pipeline Review, H1 2016’, provides an overview of the Treatment Resistant Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression
- The report reviews pipeline therapeutics for Treatment Resistant Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Treatment Resistant Depression therapeutics and enlists all their major and minor projects
- The report assesses Treatment Resistant Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Treatment Resistant Depression

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Treatment Resistant Depression
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Treatment Resistant Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics, Inc.
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Treatment Resistant Depression Overview

Therapeutics Development

Pipeline Products for Treatment Resistant Depression - Overview

Pipeline Products for Treatment Resistant Depression - Comparative Analysis

Treatment Resistant Depression - Therapeutics under Development by Companies

Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes

Treatment Resistant Depression - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Treatment Resistant Depression - Products under Development by Companies

Treatment Resistant Depression - Products under Investigation by Universities/Institutes

Treatment Resistant Depression - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Amorsa Therapeutics Inc.

Axsome Therapeutics, Inc.

Johnson & Johnson

Otsuka Holdings Co., Ltd.

Treatment Resistant Depression - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(dextromethorphan + quinidine sulfate) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMS-410 FA - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMS-520 ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AVP-786 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

esketamine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EVT-100 Series - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EVT-103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

riluzole - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VU-0431316 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Treatment Resistant Depression - Recent Pipeline Updates

Treatment Resistant Depression - Dormant Projects

Treatment Resistant Depression - Discontinued Products

Treatment Resistant Depression - Product Development Milestones

Featured News & Press Releases

Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression

Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis

Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Treatment Resistant Depression, H1 2016

Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H1 2016

Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H1 2016

Treatment Resistant Depression - Pipeline by Axsome Therapeutics, Inc., H1 2016

Treatment Resistant Depression - Pipeline by Johnson & Johnson, H1 2016

Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Treatment Resistant Depression Therapeutics - Recent Pipeline Updates, H1 2016

Treatment Resistant Depression - Dormant Projects, H1 2016

Treatment Resistant Depression - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Treatment Resistant Depression, H1 2016

Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Axsome Therapeutics, Inc.
Johnson & Johnson
Otsuka Holdings Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll